Bone Demineralization Lesions in the Injured Marrow Clinical Trial
Official title:
Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled
Subjects with lesion bone marrow are at risk of fracture by fragility bone. The median time
to onset of fracture was 8.5 years. Fracture increases costs of care, dependency.
Bone fragility is secondary to hormonal disorders and calcium phosphate, impaired excretion
of neuropeptides, vasomotor symptoms associated with the asset that promote bone loss and
architectural disorganization. These phenomena occur in the first weeks of development of
spinal cord injury and predominate in the distal femur and proximal tibia. From the third
year, the demineralization stabilizes, bone mass is estimated to be between 70 and 50% of the
initial bone mass, the new equilibrium.
No clinical evidence is predictive of fracture risk. A criteria surrogate must be used to
assess this risk. There is an association between bone mineral density and fracture risk. The
fracture threshold knee was evaluated to 0.87 g/cm2. Evaluation of bone mineral density in
the distal femur is a predictor of fracture risk. Measure reliable and reproducible, easy to
perform, it is a good element for monitoring the efficacy of anti-resorptive therapy.
n/a